🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT06812078
Recruiting Phase 2

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

NCT06812078 · tracked via the Priya Life Science USA tracker
Sponsor
Takeda
Phase
Phase 2
Started
2025-02-07
Last updated
2026-07-15

Condition(s) studied

Idiopathic Hypersomnia

Investigational drug(s) / intervention(s)

TAK-360Placebo

TAK-360: TAK-360 tablet.

Placebo: TAK-360 matching placebo tablet.

Study summary

Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness or feeling lightheaded. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake.

The main aim of this study is to learn how safe TAK-360 is and how well adults with IH tolerate it. Researchers also want to find out if TAK-360 can help people with IH stay awake and how much TAK-360 is needed to do that.

Participants will be randomly (by chance, like drawing names from a hat) chosen to receive either TAK-360 or a placebo. The placebo looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Key Inclusion Criteria: 1. The participant weighs greater than or equal to (≥) 40 kilograms (kg) and has a body mass index (BMI) between 16 and 38 kilograms per meter square (kg/m\^2) \[inclusive\]. 2. The participant has a documented, current diagnosis of IH. Key Exclusion Criteria: 1. The participant has a current medical disorder associated with excessive daytime sleepiness (EDS) \[other than IH\]. 2. The participant has medically significant thyroid disease. 3. The participant has a history of cancer in the past 5 years. (This exclusion does not apply to participants with carcinoma in situ \[such as basal cell carcinoma\] that has been treated and is stable, or who have been stable without further treatment. These participants may be included after approval by the medical monitor.) 4. The participant has any of the following viral infections based on a positive test result: Hepatitis B surface antigen (at screening), hepatitis C virus antibody (at screening), human immunodeficiency virus (HIV) antibody/antigen (at screening). 5. The participant has a clinically significant history of head injury or head trauma. 6. The participant has history of epilepsy, seizure, or convulsion (exception for a single febrile seizure in childhood). 7. The participant has a history of cerebral ischemia, transient ischemic attack (less than \[\<\]5 years from screening), intracranial aneurysm, or arteriovenous malformation.

Primary outcome measure(s)

Trial sites (29)

FacilityCityRegionStatus
Takeda Site 11 Redwood City California Recruiting
Takeda Site 10 Santa Ana California Recruiting
Takeda Site 27 Colorado Springs Colorado Recruiting
Takeda Site 19 Brandon Florida Recruiting
Takeda Site 14 Winter Park Florida Recruiting
Takeda Site 29 St Louis Missouri Recruiting
Takeda Site 16 Denver North Carolina Recruiting
Takeda Site 15 Huntersville North Carolina Recruiting
Takeda Site 12 Cincinnati Ohio Recruiting
Takeda Site 17 Cincinnati Ohio Recruiting
Takeda Site 13 Columbia South Carolina Recruiting
Takeda Site 18 San Antonio Texas Recruiting
Takeda Site 28 Norfolk Virginia Recruiting
Takeda Site 1 Montpellier Hrault Recruiting
Takeda Site 3 Nantes Pays de Loire Recruiting
Takeda Site 2 Paris France Recruiting
Takeda Site 4 Shatin Hong Kong Withdrawn
Takeda Site 6 Pozzilli Isernia Recruiting
Takeda Site 7 Rome Roma Recruiting
Takeda Site 26 Verona Veneto Recruiting
Takeda Site 5 Bologna Italy Recruiting
Takeda Site 25 Fukuoka-Shi Hakata-Ku Fukuoka Recruiting
Takeda Site 23 Kurume-shi Fukuoka Recruiting
Takeda Site 22 Kohoku-ku, Yokohama-Shi Kanagawa Recruiting
Takeda Site 20 Kumamoto Kumamoto Recruiting
Takeda Site 21 Yodogawa-ku, Osaka-shi Osaka Recruiting
Takeda Site 24 Bunkyo-ku Tokyo Recruiting
Takeda Site 9 Vitoria-Gasteiz Alava Recruiting
Takeda Site 8 Madrid Spain Recruiting

More Takeda trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06812078 on ClinicalTrials.gov ↗ ← All trials in the USA